scholarly journals Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease

2016 ◽  
Vol 131 (2) ◽  
pp. 235-246 ◽  
Author(s):  
Chengyu Zou ◽  
Yuan Shi ◽  
Jasmin Ohli ◽  
Ulrich Schüller ◽  
Mario M. Dorostkar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Structural Plasticity ◽  
Preclinical Model ◽  
Model Of Alzheimer’S Disease

scholarly journals Improved Bioavailability of Montelukast through a Novel Oral Mucoadhesive Film in Humans and Mice

Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 12
Author(s):  
Johanna Michael ◽  
Diana Bessa de Sousa ◽  
Justin Conway ◽  
Erick Gonzalez-Labrada ◽  
Rodolphe Obeid ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Neurodegenerative Diseases ◽  
Significant Proportion ◽  
Preclinical Model ◽  
Dependent Manner ◽  
Promising Alternative ◽  
Model Of Alzheimer’S Disease ◽  
Acute And Chronic Exposure

The leukotriene receptor antagonist Montelukast (MTK) is an approved medication for the treatment of asthma and allergic rhinitis. The existing marketed tablet forms of MTK exhibit inconsistent uptake and bioavailability, which partially explains the presence of a significant proportion of MTK low- and non-responders in the population. Besides that, tablets are suboptimal formulations for patients suffering from dysphagia, for example, seen in patients with neurodegenerative diseases such as Alzheimer’s disease, a disease with increasing interest in repurposing of MTK. This, and the need for an improved bioavailability, triggered us to reformulate MTK. Our aim was to develop a mucoadhesive MTK film with good safety and improved pharmacological features, i.e., an improved bioavailability profile in humans as well as in a mouse model of Alzheimer’s disease. We tested dissolution of the MTK mucoadhesive film and assessed pharmacoexposure and kinetics after acute and chronic oral application in mice. Furthermore, we performed a Phase I analysis in humans, which included a comparison with the marketed tablet form as well as a quantitative analysis of the MTK levels in the cerebrospinal fluid. The novel MTK film demonstrated significantly improved bioavailability compared to the marketed tablet in the clinical Phase 1a study. Furthermore, there were measurable amounts of MTK present in the cerebrospinal fluid (CSF). In mice, MTK was detected in serum and CSF after acute and chronic exposure in a dose-dependent manner. The mucoadhesive film of MTK represents a promising alternative for the tablet delivery. The oral film might lower the non-responder rate in patients with asthma and might be an interesting product for repurposing of MTK in other diseases. As we demonstrate Blood-Brain-Barrier (BBB) penetrance in a preclinical model, as well as in a clinical study, the oral film of MTK might find its use as a therapeutic for acute and chronic neurodegenerative diseases such as dementias and stroke.

scholarly journals Widespread Changes in Dendritic Spines in a Model of Alzheimer's Disease

2008 ◽  
Vol 19 (3) ◽  
pp. 586-592 ◽  
Author(s):  
S. Knafo ◽  
L. Alonso-Nanclares ◽  
J. Gonzalez-Soriano ◽  
P. Merino-Serrais ◽  
I. Fernaud-Espinosa ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Model Of Alzheimer’S Disease

scholarly journals RanBP9 overexpression accelerates loss of dendritic spines in a mouse model of Alzheimer's disease

2014 ◽  
Vol 69 ◽  
pp. 169-179 ◽  
Author(s):  
Ruizhi Wang ◽  
Juan Pablo Palavicini ◽  
Hongjie Wang ◽  
Panchanan Maiti ◽  
Elisabetta Bianchi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Dendritic Spines ◽  
Model Of Alzheimer’S Disease

scholarly journals A Preclinical Model of Computerized Cognitive Training: Touchscreen Cognitive Testing Enhances Cognition and Hippocampal Cellular Plasticity in Wildtype and Alzheimer’s Disease Mice

2021 ◽  
Vol 15 ◽  
Author(s):  
Amy Shepherd ◽  
Tracy Zhang ◽  
Lucas B. Hoffmann ◽  
Ariel M. Zeleznikow-Johnston ◽  
Leonid Churilov ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Performance ◽  
Cognitive Enhancement ◽  
Cognitive Testing ◽  
Preclinical Model ◽  
Cellular Plasticity ◽  
Proliferating Cells ◽  
Associate Learning ◽  
Model Of Alzheimer’S Disease

With the growing popularity of touchscreen cognitive testing in rodents, it is imperative to understand the fundamental effects exposure to this paradigm can have on the animals involved. In this study, we set out to assess hippocampal-dependant learning in the APP/PS1 mouse model of Alzheimer’s disease (AD) on two highly translatable touchscreen tasks – the Paired Associate Learning (PAL) task and the Trial Unique Non-Matching to Location (TUNL) task. Both of these tests are based on human tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB) and are sensitive to deficits in both mild cognitive impairment (MCI) and AD. Mice were assessed for deficits in PAL at 9–12 months of age, then on TUNL at 8–11 and 13–16 months. No cognitive deficits were evident in APP/PS1 mice at any age, contrary to previous reports using maze-based learning and memory tasks. We hypothesized that daily and long-term touchscreen training may have inadvertently acted as a cognitive enhancer. When touchscreen-tested mice were assessed on the Morris water maze, they showed improved task acquisition compared to naïve APP/PS1 mice and wild-type (WT) littermate controls. In addition, we show that touchscreen-trained WT and APP/PS1 mice show increased cell proliferation and immature neuron numbers in the dentate gyrus compared to behaviorally naïve WT and APP/PS1 mice. This result indicates that the touchscreen testing paradigm could improve cognitive performance, and/or mask an impairment, in experimental mouse models. This touchscreen-induced cognitive enhancement may involve increased neurogenesis, and possibly other forms of cellular plasticity. This is the first study to show increased numbers of proliferating cells and immature neurons in the hippocampus following touchscreen testing, and that touchscreen training can improve cognitive performance in maze-based spatial navigation tasks. This potential for touchscreen testing to induce cognitive enhancement, or other phenotypic shifts, in preclinical models should be considered in study design. Furthermore, touchscreen-mediated cognitive enhancement could have therapeutic implications for cognitive disorders.

scholarly journals EFAD transgenic mice as a humanAPOErelevant preclinical model of Alzheimer’s disease

2017 ◽  
Vol 58 (9) ◽  
pp. 1733-1755 ◽  
Author(s):  
Leon M. Tai ◽  
Deebika Balu ◽  
Evangelina Avila-Munoz ◽  
Laila Abdullah ◽  
Riya Thomas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Transgenic Mice ◽  
Preclinical Model ◽  
Model Of Alzheimer’S Disease

scholarly journals Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics

EBioMedicine ◽  
2021 ◽  
Vol 71 ◽  
pp. 103503
Author(s):  
Chaahat S.B. Singh ◽  
Kyung Bok Choi ◽  
Lonna Munro ◽  
Hong Yue Wang ◽  
Cheryl G. Pfeifer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Advanced Cancer ◽  
Cancer Therapeutics ◽  
Preclinical Model ◽  
Model Of Alzheimer’S Disease

Layer-specific alterations to CA1 dendritic spines in a mouse model of Alzheimer's disease

Hippocampus ◽  
2010 ◽  
Vol 21 (10) ◽  
pp. 1037-1044 ◽  
Author(s):  
P. Merino-Serrais ◽  
S. Knafo ◽  
L. Alonso-Nanclares ◽  
I. Fernaud-Espinosa ◽  
J. DeFelipe
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Dendritic Spines ◽  
Model Of Alzheimer’S Disease
Sign in / Sign up

Export Citation Format

Share Document